Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Pharmacokinetic and pharmacodynamic characteristics of emicizumab in Chinese pediatric patients with hemophilia A: A retrospective single-center study

Qianqian Mao, Zhengping Li, Zhenping Chen, Runhui Wu

Blood (2025) 146 (Supplement 1): 6614.

https://doi.org/10.1182/blood-2025-6614

Published: 2025

Journal Articles

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: Results from a randomized, multicenter, placebo-controlled phase 3 trial

Runhui Wu, Ju Gao, Yufeng Liu, Jie Yu, Shaoyan Hu, Hui Liang, Hui Jiang, Xiaowen Zhai, Min Zhou, Wenge Hao, Heng Mei, Fei Li, Yumei Chen, Wei Liu, Mei Yan, Runzi Li, Junye Xiong, Zhenyi Zhu, Tianyou Wang

Blood (2025) 146 (Supplement 1): 4804.

https://doi.org/10.1182/blood-2025-4804

Published: 2025

Journal Articles

Real-world outcomes of PK/PD-guided individualized emicizumab dose reduction in Chinese pediatric patients with hemophilia A: A prospective observational study

Qianqian Mao, Zhengping Li, Zhenping Chen, Runhui Wu

Blood (2025) 146 (Supplement 1): 4840.

https://doi.org/10.1182/blood-2025-4840

Published: 2025

Journal Articles

The R and CI Values from Thromboelastography (TEG) May be the Risk Predictors for Low-Dose Emicizumab in Chinese Pediatric Hemophilia Patients

Qianqian Mao, Zhengping Li, Qixaun Yin, Gang Li, Zhenping Chen, Runhui Wu

Blood (2024) 144 (Supplement 1): 3971.

https://doi.org/10.1182/blood-2024-211678

Published: 2024

Journal Articles

The Real-World Data of Emicizumab in Previously Untreated and Minimally Treated Patients with Hemophilia a Infants from China

Qixaun Yin, Qianqian Mao, Zhengping Li, Gang Li, Zhenping Chen, Runhui Wu

Blood (2024) 144 (Supplement 1): 5483.

https://doi.org/10.1182/blood-2024-209421

Published: 2024

Journal Articles

Dynamic Changes in Factor VIII Inhibitor Titers in Severe Hemophilia A Patients with Inhibitors Receiving Emicizumab Prophylaxis

Zhengping Li, Qianqian Mao, Qixaun Yin, Zhenping Chen, Runhui Wu

Blood (2024) 144 (Supplement 1): 5481.

https://doi.org/10.1182/blood-2024-211977

Published: 2024

Journal Articles

Therapeutic Potential of Roxadustat in Immune Thrombocytopenia: A Mendelian Randomization Analysis

Jingyao Ma, Runhui Wu

Blood (2024) 144 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2024-199439

Published: 2024

Journal Articles

Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study

Marie Scully, Claire Berger, Nathalie Biebuyck, Santiago Bonanad Boix, Claire Dossier, Wolf-Achim Hassenpflug, Karim Kentouche, Beverly Schaefer, Silvia Maria Trisolini, Runhui Wu, Juan Xiao, Feng Xue, Björn Mellgård, Munjal Patel, Parth Patwari, Linda T. Wang, Shan Xiao, Pinghai Zhang

Blood (2024) 144 (Supplement 1): 141.

https://doi.org/10.1182/blood-2024-199087

Published: 2024

Journal Articles

The Efficacy and Safety of Huaiqihuang Granules in the Treatment of Childhood Chronic Primary Immune Thrombocytopenia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Clinical Study

Juan Han, Fen Zhou, Runming Jin, Xiaodong Shi, Jianxin Li, Yongjun Fang, Xiaojun Yuan, Xuequn Luo, Jianqin Li, Lirong Sun, Wenjun Liu, Mei Yan, Yufeng Liu, Changda Liang, Hua Jiang, Runhui Wu

Blood (2024) 144 (Supplement 1): 5461.

https://doi.org/10.1182/blood-2024-210064

Published: 2024

Journal Articles

Adding Eltrombopag to Intensive Immunosuppressive Therapy Helps Adult Patients Catch up Pediatric Patients in Severe Aplastic Anemia

Bixi Yang, Leyu Wang, Lingling Fu, Runhui Wu, Jie Ma, Miao Chen, Bing Han

Blood (2024) 144 (Supplement 1): 5247.

https://doi.org/10.1182/blood-2024-193483

Published: 2024

Journal Articles

A Better Efficacy of an Escalating Strategy over Thrombopoietin Receptor Agonist-Based Second-Line Therapy in Children Severe Persistent/Chronic Thrombocytopenia: A Multicenter Prospective Study from China

Runhui Wu, Lingling Fu, Xi Lin

Blood (2024) 144 (Supplement 1): 5424.

https://doi.org/10.1182/blood-2024-199447

Published: 2024

Journal Articles

Long-Term Eltrombopag in Children with Chronic Immune Thrombocytopenia: A Single-Center Extended Real-Life Observational Study in China

Zhifa Wang, Nan Wang, Juntao Ouyang, Jingyao Ma, Man-Chiu Poon, Zhenping Chen, Xiaoling Cheng, Runhui Wu

Blood (2023) 142 (Supplement 1): 2590.

https://doi.org/10.1182/blood-2023-185812

Published: 2023

Journal Articles

Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 2624.

https://doi.org/10.1182/blood-2023-174698

Published: 2023

Journal Articles

Low-Dose Immune Tolerance Induction Therapy for Severe Hemophilia a Inhibitor Patients: Immunosuppressants Improve Outcomes but Are Generally Not Necessary for Inhibitor-Titer below 200 BU/Ml

Zhengping Li, Man-Chiu Poon, Runhui Wu

Blood (2023) 142 (Supplement 1): 3988.

https://doi.org/10.1182/blood-2023-184514

Published: 2023

Journal Articles

Chinese Severe Hemophilia a Children with High-Titer Inhibitors Obtain More Benefit from Intermediate-Dose Immune Tolerance Induction: The Interim Result of Lome Part a

Zhengping Li, Runhui Wu

Blood (2023) 142 (Supplement 1): 5478.

https://doi.org/10.1182/blood-2023-185290

Published: 2023

Journal Articles

F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B

Guoqing Liu, Jie Sun, Zekun Li, Zhenping Chen, Wenman Wu, Runhui Wu

Blood (2023) 141 (6): 677–680.

https://doi.org/10.1182/blood.2022017871

Published: 2023

Journal Articles

Protocol and Primary Analysis of Lome: A Randomized Trial of Low- Versus Intermediate-Dose Immune Tolerance Induction with Recombinant Factor VIII (Omfiloctocog alfa, SCT800) in China

Zhengping Li, Guoqing Liu, Zhen Yingzi, Xiaoling Cheng, Zhenping Chen, Di Ai, Zekun Li, Jie Sun, Kun Huang, Sr., Runhui Wu

Blood (2022) 140 (Supplement 1): 5615–5616.

https://doi.org/10.1182/blood-2022-164951

Published: 2022

Journal Articles

Single-Cell Sequencing of Immune Cells from Hemophilia a Patients with Inhibitors and Acquired Hemophilia a Patients

Enhao Li, Zekun Li, Jing Dai, Guoqing Liu, Jie Sun, Zhenping Chen, Runhui Wu, Xuefeng Wang, Wenman WU

Blood (2022) 140 (Supplement 1): 8428–8429.

https://doi.org/10.1182/blood-2022-169345

Published: 2022

Journal Articles

Shorter Time Interval from Inhibitor Detection to Starting Low-Dose Immune Tolerance Induction Therapy Is Associated with Better Inhibitor Eradication Outcomes in Severe Hemophilia a Children with High-Titer Inhibitors in China

Zhengping Li, Man-Chiu Poon, Guoqing Liu, Zekun Li, Jie Sun, Runhui Wu

Blood (2022) 140 (Supplement 1): 2757–2758.

https://doi.org/10.1182/blood-2022-164999

Published: 2022

Journal Articles

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 8468–8469.

https://doi.org/10.1182/blood-2022-158760

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Pharmacokinetic and pharmacodynamic characteristics of emicizumab in Chinese pediatric patients with hemophilia A: A retrospective single-center study

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: Results from a randomized, multicenter, placebo-controlled phase 3 trial

Real-world outcomes of PK/PD-guided individualized emicizumab dose reduction in Chinese pediatric patients with hemophilia A: A prospective observational study

The R and CI Values from Thromboelastography (TEG) May be the Risk Predictors for Low-Dose Emicizumab in Chinese Pediatric Hemophilia Patients

The Real-World Data of Emicizumab in Previously Untreated and Minimally Treated Patients with Hemophilia a Infants from China

Dynamic Changes in Factor VIII Inhibitor Titers in Severe Hemophilia A Patients with Inhibitors Receiving Emicizumab Prophylaxis

Therapeutic Potential of Roxadustat in Immune Thrombocytopenia: A Mendelian Randomization Analysis

Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study

The Efficacy and Safety of Huaiqihuang Granules in the Treatment of Childhood Chronic Primary Immune Thrombocytopenia: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Clinical Study

Adding Eltrombopag to Intensive Immunosuppressive Therapy Helps Adult Patients Catch up Pediatric Patients in Severe Aplastic Anemia

A Better Efficacy of an Escalating Strategy over Thrombopoietin Receptor Agonist-Based Second-Line Therapy in Children Severe Persistent/Chronic Thrombocytopenia: A Multicenter Prospective Study from China

Long-Term Eltrombopag in Children with Chronic Immune Thrombocytopenia: A Single-Center Extended Real-Life Observational Study in China

Emicizumab Prophylaxis for the Treatment of Chinese Hemophilia A Patients in the Real World: A Multi-Center Retrospective Analysis

Low-Dose Immune Tolerance Induction Therapy for Severe Hemophilia a Inhibitor Patients: Immunosuppressants Improve Outcomes but Are Generally Not Necessary for Inhibitor-Titer below 200 BU/Ml

Chinese Severe Hemophilia a Children with High-Titer Inhibitors Obtain More Benefit from Intermediate-Dose Immune Tolerance Induction: The Interim Result of Lome Part a

F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B

Protocol and Primary Analysis of Lome: A Randomized Trial of Low- Versus Intermediate-Dose Immune Tolerance Induction with Recombinant Factor VIII (Omfiloctocog alfa, SCT800) in China

Single-Cell Sequencing of Immune Cells from Hemophilia a Patients with Inhibitors and Acquired Hemophilia a Patients

Shorter Time Interval from Inhibitor Detection to Starting Low-Dose Immune Tolerance Induction Therapy Is Associated with Better Inhibitor Eradication Outcomes in Severe Hemophilia a Children with High-Titer Inhibitors in China

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only